Vyndaqel and Hyperkalemia - a phase IV clinical study of FDA data

Summary:

Hyperkalemia is reported as a side effect among people who take Vyndaqel (tafamidis meglumine), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Nexium, and have Cardiac amyloidosis.

The phase IV clinical study analyzes which people have Hyperkalemia when taking Vyndaqel. It is created by eHealthMe based on reports of 3,783 people who have side effects when taking Vyndaqel from the FDA, and is updated regularly.

What is Vyndaqel?

Vyndaqel has active ingredients of tafamidis meglumine. eHealthMe is studying from 3,783 Vyndaqel users. Check the latest studies of Vyndaqel.

What is Hyperkalemia?

Hyperkalemia (damage to or disease of the kidney) is found to be associated with 1,957 drugs and 2,936 conditions by eHealthMe. Check the latest studies of Hyperkalemia.

On Jul, 11, 2026

3,783 people reported to have side effects when taking Vyndaqel.
Among them, 14 people (0.37%) have Hyperkalemia.

Among these 14 people:

How long have people been on Vyndaqel when they have Hyperkalemia? *

What is the gender of people who have Hyperkalemia when taking Vyndaqel? *

female: 28.57 %
male: 71.43 %

What is the age of people who have Hyperkalemia when taking Vyndaqel? *

What are other drugs people take besides Vyndaqel? *

What are other side effects people have besides Hyperkalemia? *

Renal Impairment (severely reduced kidney function): 4 people, 28.57%
Fall: 4 people, 28.57%
Cardiac Failure: 3 people, 21.43%
Weight Decreased: 2 people, 14.29%
Fatigue (feeling of tiredness): 2 people, 14.29%
Acute Kidney Failure: 2 people, 14.29%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 2 people, 14.29%
Therapeutic Response Unexpected: 2 people, 14.29%
Death: 2 people, 14.29%
Dehydration (dryness resulting from the removal of water): 2 people, 14.29%

What are the existing conditions these people have? *

Cardiac Amyloidosis (protein deposition in heart): 8 people, 57.14%
Fluid Retention (an abnormal accumulation of fluid in the blood): 3 people, 21.43%
Cardiac Failure: 3 people, 21.43%
Cardiac Disorder: 3 people, 21.43%
Gastritis (inflammation of stomach): 2 people, 14.29%
Chronic Kidney Disease: 2 people, 14.29%
Blood Pressure Abnormal: 2 people, 14.29%
Atrial Tachycardia (rhythm disturbance that arises in the atria): 2 people, 14.29%
Amyloidosis (a tumour within which amyloid is produced): 2 people, 14.29%
Hypokalemia (low potassium): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Vyndaqel and have Hyperkalemia?

- Check whether Hyperkalemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Vyndaqel:

Vyndaqel (3,783 reports)

Hyperkalemia treatments and more:

Hyperkalemia (78,084 reports)

Browse all side effects of Vyndaqel:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperkalemia:

Hyperkalemia (1,957 drugs)

Browse all the conditions that are associated with Hyperkalemia:

Hyperkalemia (2,936 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tafamidis meglumine (the active ingredients of Vyndaqel) and Vyndaqel (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.